Targeted Delivery of Genome Editors: A Dinner Table Summary
Link to Article: https://doi.org/10.1038/s41587-025-02945-w
Executive Summary (The Elevator Pitch)
CRISPR and other gene editing tools can now fix disease-causing mutations, but the major challenge is delivering these molecular scissors to the right cells in the body without affecting healthy tissues. This review describes four main strategies researchers are using—choosing the right injection route, attaching molecular "address labels," controlling where editors turn on, and selecting gene targets that only matter in diseased cells—with most current clinical successes focused on liver diseases. The authors argue that the future of gene therapy requires combining multiple targeting strategies to achieve the precision of a "magic bullet" that hits only its intended target.
Authors and Institutions
Lead Authors:
- Wayne Ngo, Jamie L. Y. Wu, Kevin M. Wasko
- Jennifer A. Doudna (senior/corresponding author, Nobel Prize winner for CRISPR discovery)
Institutions:
- UC Berkeley Innovative Genomics Institute
- Gladstone Institutes
- Howard Hughes Medical Institute
- Lawrence Berkeley National Laboratory
Conflicts of Interest:
- Doudna has extensive commercial ties: cofounder of 6 biotech companies (Caribou, Editas, Scribe, Mammoth, and others), serves on scientific advisory boards, holds equity positions, and has patents on CRISPR technologies
- Ngo also listed as co-inventor on delivery technology patents
- Funding from HHMI, NIH, DOE, and private sources including Apple Tree Partners
Key Data and Findings
Clinical Trials Discussed:
- NTLA-2001: IV-delivered CRISPR for transthyretin amyloidosis (87% protein reduction)
- BRILLIANCE: Eye injection for Leber congenital amaurosis (6 of 14 patients improved)
- VERVE-101/201: Base editors for cholesterol disorders targeting PCSK9 and ANGPTL3
- Multiple ongoing trials: For hereditary angioedema, α1-antitrypsin deficiency, muscular dystrophy, HIV, and others
Four Main Targeting Strategies Reviewed:
- Administration route (where you inject): Eye, muscle, brain, IV, oral, etc.
- Molecular targeting (cellular zip codes): Antibodies, sugar molecules (GalNAc), engineered viral capsids
- Expression control (genetic switches): Tissue-specific promoters, microRNA regulation
- Gene target selection (phenotypic specificity): Targeting genes only active in diseased cells
Strengths (What They Got Right)
Comprehensive Framework
- Provides clear conceptual model: targeting as "layers of selection filters" that progressively narrow specificity from organ → cell → subcellular → genetic levels
Honest About Limitations
- Acknowledges that liver is currently the "low-hanging fruit" because IV delivery naturally accumulates there; admits other organs remain challenging
Clinical Relevance
- Extensively covers ongoing trials and near-term therapeutic applications, not just theoretical possibilities
Balanced Coverage
- Reviews multiple delivery platforms (AAV viruses, lipid nanoparticles, engineered vesicles, direct protein delivery) with fair assessment of trade-offs
Important Mechanistic Insight
- Distinguishes between where editors physically go versus where they're expressed versus where they have functional effects—a crucial distinction often conflated
Call for Better Methods
- Emphasizes need for quantitative tracking of actual editor biodistribution, not just measuring activity endpoints that can be misleading
Weaknesses (What to Question)
No New Experimental Data
- This is a review article synthesizing others' work, so presents no novel findings or independent validation
Potential Bias from Conflicts
- Authors have significant financial stakes in genome editing companies; may overstate near-term potential or underplay competitors' approaches
Limited on Practical Barriers
- Minimal discussion of manufacturing challenges, costs ($2-3 million per patient for some gene therapies), or equitable access issues
Liver-Centric Success Story
- Most clinical wins are in liver because it naturally captures IV particles; progress in brain, muscle, lung more limited than framing suggests
Immunogenicity Underplayed
- Discusses immune responses but may underemphasize how preexisting immunity to AAV (40-60% of population) and anti-Cas9 antibodies limit repeat dosing
Safety Data Still Emerging
- Recent high-profile AAV toxicity deaths in other trials not fully addressed; long-term integration risks of some approaches mentioned but minimized
"Magic Bullet" Framing
- Aspirational language about achieving perfect specificity may oversell realistic near-term capabilities
Rapidly Dating Material
- Published January 2026 but knowledge cutoff was January 2025; field moves fast enough that landscape shifts quarterly
Bottom Line for Dinner Conversation
This is an authoritative overview from Jennifer Doudna's lab (she won the Nobel for inventing CRISPR) explaining why delivering gene editors to the right place in the body is harder than the editing itself. The good news: it's working for some liver diseases and eye conditions in clinical trials right now. The reality check: most organs remain difficult to target precisely, costs are astronomical, and we're probably 5-10 years from routine multi-organ gene therapy. The framework of combining multiple targeting layers (injection site + molecular targeting + expression control + gene choice) is intellectually useful, though the authors' extensive biotech company ties mean taking their optimism with a grain of salt about timelines and which approaches will ultimately succeed.